Researchers have discovered that disruptions in the brain’s salience network, often tied to tau protein buildup, correlate strongly with behavioral changes in people with early-stage dementia.

The drug is RI-AG03, and it's a peptide inhibitor (a blocker of proteins). In tests on fruit flies and human cells, it has ...

A new drug targeting Tau protein shows promise in preventing its accumulation, potentially leading to more effective ...

Further research could also help explain and even predict variation in the onset of behavioral changes in people with ...

Researchers from the University of Michigan reveal new insights into early-stage dementia, identifying tau protein as a ...

When most people think of dementia, particularly Alzheimer’s disease, they often think of memory loss first. However, ...

Researchers make promising breakthrough in Alzheimer’s drug development: Lancaster Monday, October 7, 2024, 11:00 Hrs [IST] An international team of researchers led by Lancaster ...

GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson’s Disease ModelsGT-02287 Improves Mitochondrial Function ...

In two papers, published in Cell and Science, they demonstrate how utilizing the unique capabilities of a protein called TRIM21 gives the potential therapies two key advantages. Firstly, they only ...

Scientists have announced a significant breakthrough in the development of a drug to combat Alzheimer's disease. The drug, ...